摘要
目的:探讨替米沙坦联合前列地尔治疗糖尿病肾病的疗效。方法:将79例2型糖尿病肾病患者随机分为A组25例、B组27例,C组27例。在达到血糖和血压控制目标且稳定1周后,A组给予前列地尔治疗,B组给予替米沙坦,C组联合用药,进行4周临床观察治疗,分别比较三组24h尿微量白蛋白(UAE)、血尿素氮(BUN)、血肌酐(Scr)、尿肌酐(UCr)、空腹血糖(FBG)、平均动脉压(舒张压+1/3脉压差,MAP)等指标变化;并观察治疗期间的药品不良反应。结果:治疗4周后,24h尿微量白蛋白和MAP等指标都较治疗前均有明显好转(P<0.05);另外联合治疗组的疗效优于前列地尔组和替米沙坦组,结果具有统计学意义。结论:替米沙坦联合前列地尔能够有效治疗糖尿病肾病。
Objective： To observe the effects of combined telmisartan with alprostadil in treating diabetic nephropathy.Method：79 patients with type 2 diabetes complicating with diabetic nephropathy were randomly divided into group A（25 cases,alprostadil group）,group B（27 cases,telmisartan）,and group C（27 cases,combined medication）.After 4-week treatment,the 24 hour urinary albumin excretion（24h UAE）,blood urea nitrogen（BUN）,serum creatinine（Scr）,urine creatinine（Ucr）,fasting blood glucose（FBG）,MAP were detected and compared among the three groups.And,drug adverse reactions were observed.Result：After 4-week treatment,24h urine protein excretion and MAP all were obviously reduced among the three groups compared with before treatment（P0.05）;Another combination therapy was more effective than alprostadil group and telmisartan group,the results were statistically significant.Conclusion：Combined telmisartan with alprostadil in treating diabetic nephropathy is an effective method.
出处
《河北医学》
CAS
2012年第3期371-373,共3页
Hebei Medicine
